Research Article| Volume 27, ISSUE 11, P1165-1174, November 2021

Download started.


Association Between β-Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry



      β-Blockers have an uncertain effect in heart failure with a preserved ejection fraction of 50% or higher (heart failure with preserved ejection fraction [HFpEF]).

      Methods and Results

      We included patients with HFpEF from the Swedish Heart Failure Registry (SwedeHF) enrolled from 2011 through 2018. In a 2:1 propensity-score matched analysis (β-blocker use vs nonuse), we assessed the primary outcome first HF hospitalization, the coprimary outcome cardiovascular (CV) death, and the secondary outcomes of all-cause hospitalization and all-cause death. We performed intention-to-treat and a per-protocol consistency analyses. There were a total of 14,434 patients (median age 79 years, IQR 71–85 years, 51% women); 80% were treated with a β-blocker at baseline. Treated patients were younger and had higher rates of atrial fibrillation and coronary artery disease, and higher N-terminal pro-B-type natriuretic peptide levels. In the 4412:2206 patient matched cohort, at 5 years, 42% (95% CI 40%–44%) vs 44% (95% CI 41%–47%) had a HF admission and 38% (IQR 36%–40%) vs 40% (IQR 36%–42%) died from CV causes. In the intention-to-treat analysis, β-blocker use was not associated with HF admissions (hazard ratio 0.95 [95% CI 0.87–1.05, P = .31]) or CV death (hazard ratio 0.94 [95% CI 0.85–1.03, P = .19]). In the subgroup analyses, men seemed to have a more favorable association between β-blockers and outcomes than did women. There were no associations between β-blocker use and secondary outcomes.


      In patients with HFpEF, β-blocker use is common but not associated with changes in HF hospitalization or cardiovascular mortality. In the absence of a strong rational and randomized control trials the case for β-blockers in HFpEF remains inconclusive.

      Bullet points

      ● The effect of β-blockers with heart failure with preserved ejection fraction of 50% or greater is uncertain.● In a propensity score–matched heart failure with preserved ejection fraction analysis in the SwedeHF registry, β-blockers were not associated with a change in risk for heart failure admissions or cardiovascular deaths.

      Lay summary

      The optimal treatment for heart failure with a preserved pump function remains unknown. Despite the lack of scientific studies, β-blockers are very commonly used. When matching patients with a similar risk profile in a large heart failure registry, the use of β-blockers for the treatment of heart failure with a preserved pump function was not associated with any changes in heart failure hospital admissions or cardiovascular death.

      Graphical Abstract

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yancy CW
        • Jessup M
        • Bozkurt B
        • Butler J
        • Casey DE
        • Drazner MH
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        Circulation. 2013; 128: e240-e327
        • Owan TE
        • Hodge DO
        • Herges RM
        • Jacobsen SJ
        • Roger VL
        • Redfield MM.
        Trends in prevalence and outcome of heart failure with preserved ejection fraction.
        N Engl J Med. 2006; 355: 251-259
        • Loop MS
        • Van Dyke MK
        • Chen L
        • Brown TM
        • Durant RW
        • Safford MM
        • et al.
        Comparison of length of stay, 30-day mortality, and 30-day readmission rates in Medicare patients with heart failure and with reduced versus preserved ejection fraction.
        Am J Cardiol. 2016; 118: 79-85
        • Lewis EF
        • Lamas GA
        • O'Meara E
        • Granger CB
        • Dunlap ME
        • McKelvie RS
        • et al.
        Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
        Eur J Heart Fail. 2007; 9: 83-91
        • Cleland JGF
        • Bunting KV
        • Flather MD
        • Altman DG
        • Holmes J
        • Coats AJS
        • et al.
        Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
        Eur Heart J. 2018; 39: 26-35
        • Yancy CW
        • Lopatin M
        • Stevenson LW
        • De Marco T
        • Fonarow GC
        • ADHERE Scientific Advisory Committee and Investigators
        Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.
        J Am Coll Cardiol. 2006; 47: 76-84
        • Solomon SD
        • McMurray JJV
        • PARAGON_HF Steering Committee and Investigators
        Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Reply.
        N Engl J Med. 2020; 382: 1182-1183
        • Meyer M
        • LeWinter MM.
        Heart rate and heart failure with preserved ejection fraction: time to slow β-blocker use?.
        Circ Heart Fail. 2019; 12e006213
        • Savarese G
        • Vasko P
        • Jonsson Å
        • Edner M
        • Dahlström U
        • Lund LH.
        The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure.
        Ups J Med Sci. 2019; 124: 65-69
        • Jonsson A
        • Edner M
        • Alehagen U
        • Dahlström U.
        Heart failure registry: a valuable tool for improving the management of patients with heart failure.
        Eur J Heart Fail. 2010; 12: 25-31
        • Lund LH
        • Benson L
        • Dahlström U
        • Edner M
        • Friberg L.
        Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
        JAMA. 2014; 312: 2008-2018
        • Ingelsson E
        • Arnlöv J
        • Sundström J
        • Lind L.
        The validity of a diagnosis of heart failure in a hospital discharge register.
        Eur J Heart Fail. 2005; 7: 787-791
        • Mitra R
        • Reiter JP.
        A comparison of two methods of estimating propensity scores after multiple imputation.
        Stat Methods Med Res. 2016; 25: 188-204
        • Fine JP
        • Gray RJ.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509
        • Pitt B
        • Pfeffer MA
        • Assmann SF
        • Boineau R
        • Anand IS
        • Claggett B
        • et al.
        Spironolactone for heart failure with preserved ejection fraction.
        N Engl J Med. 2014; 370: 1383-1392
        • Shah AM
        • Cikes M
        • Prasad N
        • Li G
        • Getchevski S
        • Claggett B
        • et al.
        Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction.
        J Am Coll Cardiol. 2019; 74: 2858-2873
        • Flather MD
        • Shibata MC
        • Coats AJ
        • Van Veldhuisen DJ
        • Parkhomenko A
        • Borbola J
        • et al.
        Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
        Eur Heart J. 2005; 26: 215-225
        • Yamamoto K
        • Origasa H
        • Hori M
        • Investigators J-D.
        Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).
        Eur J Heart Fail. 2013; 15: 110-118
        • Zhou J
        • Shi H
        • Zhang J
        • Lu Y
        • Fu M
        • Ge J
        • et al.
        Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study.
        Eur J Heart Fail. 2010; 12: 181-185
        • Martin N
        • Manoharan K
        • Thomas J
        • Davies C
        • Lumbers RT.
        Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
        Cochrane Database Syst Rev. 2018; 6CD012721
        • Hernandez AF
        • Hammill BG
        • O'Connor CM
        • Schulman KA
        • Curtis LH
        • Fonarow GC
        Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
        J Am Coll Cardiol. 2009; 53: 184-192
        • Bavishi C
        • Chatterjee S
        • Ather S
        • Patel D
        • Messerli FH.
        Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis.
        Heart Fail Rev. 2015; 20: 193-201
        • Silverman DN
        • Plante TB
        • Infeld M
        • Callas PW
        • Juraschek SP
        • Dougherty GB
        • et al.
        Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial.
        JAMA Netw Open. 2019; 2e1916598
        • Fu EL
        • Uijl A
        • Dekker FW
        • Lund LH
        • Savarese G
        • Carrero JJ.
        Association between β-blocker use and mortality/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease.
        Circ Heart Fail. 2020; 13e007180
        • Tsujimoto T
        • Kajio H.
        Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction.
        Sci Rep. 2018; 8: 9556
        • Bergström A
        • Andersson B
        • Edner M
        • Nylander E
        • Persson H
        • Dahlström U.
        Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
        Eur J Heart Fail. 2004; 6: 453-461
        • Edelmann F
        • Musial-Bright L
        • Gelbrich G
        • Trippel T
        • Radenovic S
        • Wachter R
        • et al.
        Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: insights from the CIBIS-ELD trial.
        JACC Heart Fail. 2016; 4: 140-149
        • Nambiar L
        • Silverman D
        • Vanburen P
        • LeWinter M
        • Meyer M.
        Beta-blocker cessation in stable outpatients with heart failure with a preserved ejection fraction.
        J Card Fail. 2020; 26: 281-282
        • Dahlöf B
        • Devereux RB
        • Kjeldsen SE
        • Julius S
        • Beevers G
        • de Faire U
        • et al.
        Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Kotecha D
        • Bunting KV
        • Gill SK
        • Mehta S
        • Stanbury M
        • Jones JC
        • et al.
        Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial.
        JAMA. 2020; 324: 2497-2508
        • Chen ZM
        • Pan HC
        • Chen YP
        • Peto R
        • Collins R
        • Jiang LX
        • et al.
        Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
        Lancet. 2005; 366: 1622-1632
        • Bangalore S
        • Makani H
        • Radford M
        • Thakur K
        • Toklu B
        • Katz SD
        • et al.
        Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials.
        Am J Med. 2014; 127: 939-953
        • Motivala AA
        • Parikh V
        • Roe M
        • Dai D
        • Abbott JD
        • Prasad A
        • et al.
        Predictors, trends, and outcomes (among older patients ≥65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR Registry.
        JACC Cardiovasc Interv. 2016; 9: 1639-1648
        • Ulimoen SR
        • Enger S
        • Pripp AH
        • Abdelnoor M
        • Arnesen H
        • Gjesdal K
        • et al.
        Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
        Eur Heart J. 2014; 35: 517-524
        • Bots SH
        • Groepenhoff F
        • Eikendal ALM
        • Tannenbaum C
        • Rochon PA
        • Regitz-Zagrosek V
        • et al.
        Adverse drug reactions to guideline-recommended heart failure drugs in women: a systematic review of the literature.
        JACC Heart Fail. 2019; 7: 258-266
        • Bots SH
        • den Ruijter HM.
        Recommended heart failure medications and adverse drug reactions in women.
        Circulation. 2019; 139: 1469-1471
        • Unlu O
        • Levitan EB
        • Reshetnyak E
        • Kneifati-Hayek J
        • Diaz I
        • Archambault A
        • et al.
        Polypharmacy in older adults hospitalized for heart failure.
        Circ Heart Fail. 2020; 13e006977